# Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

> **NCT03684044** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 363 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Baloxavir Marboxil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03684044
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-08
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-16
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684044, "Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03684044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*